# PetVivo Holdings, Inc.: financial statements, quarterly

PETV · OTC · CIK 1512922 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/petv.md) · [Financials](/companies/petv/financials.md) · [Filings](/companies/petv/filings.md) · [Insiders](/companies/petv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/petv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [207](/filings/0001493152-24-045778.md) | [596](/filings/0001493152-25-006783.md) | [48.3 d](/filings/0001641172-25-018617.md) | [124](/filings/0001493152-25-011967.md) | [201](/filings/0001493152-25-023398.md) | [583](/filings/0001493152-26-007150.md) | [225 d](/filings/0001493152-26-031136.md) | [298](/filings/0001493152-26-038477.md) | [303](/filings/0001493152-25-023398.md) | [286](/filings/0001493152-26-007150.md) | [255 d](/filings/0001493152-26-031136.md) | [338](/filings/0001493152-26-038477.md) |
| Cost of revenue | $k | [21.9](/filings/0001493152-24-045778.md) | [62.6](/filings/0001493152-25-006783.md) | [5.2 d](/filings/0001641172-25-018617.md) | [13.0](/filings/0001493152-25-011967.md) | [21.2](/filings/0001493152-25-023398.md) | [61.5](/filings/0001493152-26-007150.md) | [42.0 d](/filings/0001493152-26-031136.md) | [111](/filings/0001493152-26-038477.md) | [83.2](/filings/0001493152-25-023398.md) | [141](/filings/0001493152-26-007150.md) | [51.5 d](/filings/0001493152-26-031136.md) | [114](/filings/0001493152-26-038477.md) |
| Gross profit | $k | [186](/filings/0001493152-24-045778.md) | [533](/filings/0001493152-25-006783.md) | [43.1 d](/filings/0001641172-25-018617.md) | [111](/filings/0001493152-25-011967.md) | [180](/filings/0001493152-25-023398.md) | [522](/filings/0001493152-26-007150.md) | [183 d](/filings/0001493152-26-031136.md) | [187](/filings/0001493152-26-038477.md) | [220](/filings/0001493152-25-023398.md) | [145](/filings/0001493152-26-007150.md) | [203 d](/filings/0001493152-26-031136.md) | [223](/filings/0001493152-26-038477.md) |
| Research and development | $k | [359](/filings/0001493152-24-045778.md) | [352](/filings/0001493152-25-006783.md) | [391 d](/filings/0001641172-25-018617.md) | [388](/filings/0001493152-25-011967.md) | [465](/filings/0001493152-25-023398.md) | [372](/filings/0001493152-26-007150.md) | [359 d](/filings/0001493152-26-031136.md) | [341](/filings/0001493152-26-038477.md) | [261](/filings/0001493152-25-023398.md) | [323](/filings/0001493152-26-007150.md) | [490 d](/filings/0001493152-26-031136.md) | [233](/filings/0001493152-26-038477.md) |
| Operating income | $k | [(2,944)](/filings/0001493152-24-045778.md) | [(2,134)](/filings/0001493152-25-006783.md) | [(2,650) d](/filings/0001641172-25-018617.md) | [(2,044)](/filings/0001493152-25-011967.md) | [(2,173)](/filings/0001493152-25-023398.md) | [(1,758)](/filings/0001493152-26-007150.md) | [(2,080) d](/filings/0001493152-26-031136.md) | [(1,844)](/filings/0001493152-26-038477.md) | [(2,065)](/filings/0001493152-25-023398.md) | [(2,191)](/filings/0001493152-26-007150.md) | [(2,962) d](/filings/0001493152-26-031136.md) | [(1,609)](/filings/0001493152-26-038477.md) |
| Interest expense | $k | not reported | not reported | not reported | [2.6](/filings/0001493152-25-011967.md) | [2.5](/filings/0001493152-25-023398.md) | [0.5](/filings/0001493152-26-007150.md) | [5.7 d](/filings/0001493152-26-031136.md) | [122](/filings/0001493152-26-038477.md) | [942](/filings/0001493152-25-023398.md) | [0.0](/filings/0001493152-26-007150.md) | [1.4 d](/filings/0001493152-26-031136.md) | [5.0](/filings/0001493152-26-038477.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,661)](/filings/0001493152-25-006783.md) | [(1,750)](/filings/0001493152-25-006783.md) | [(2,651) d](/filings/0001641172-25-018617.md) | [(2,047)](/filings/0001493152-26-007150.md) | [(2,175)](/filings/0001493152-26-007150.md) | [(1,757)](/filings/0001493152-26-007150.md) | [(2,420) d](/filings/0001493152-26-031136.md) | [(2,311)](/filings/0001493152-26-038477.md) | [(3,008)](/filings/0001493152-26-007150.md) | [(2,191)](/filings/0001493152-26-007150.md) | [(2,963) d](/filings/0001493152-26-031136.md) | [(1,614)](/filings/0001493152-26-038477.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0001493152-24-045778.md) | [(0.12)](/filings/0001493152-25-006783.md) | not reported | [(0.11)](/filings/0001493152-25-011967.md) | [(0.11)](/filings/0001493152-25-023398.md) | [(0.09)](/filings/0001493152-26-007150.md) | not reported | [(0.10)](/filings/0001493152-26-038477.md) | [(0.11)](/filings/0001493152-25-023398.md) | [(0.07)](/filings/0001493152-26-007150.md) | not reported | [(0.05)](/filings/0001493152-26-038477.md) |
| Basic EPS | $ per share | [(0.28)](/filings/0001493152-24-045778.md) | [(0.12)](/filings/0001493152-25-006783.md) | not reported | [(0.11)](/filings/0001493152-25-011967.md) | [(0.11)](/filings/0001493152-25-023398.md) | [(0.09)](/filings/0001493152-26-007150.md) | not reported | [(0.10)](/filings/0001493152-26-038477.md) | [(0.11)](/filings/0001493152-25-023398.md) | [(0.07)](/filings/0001493152-26-007150.md) | not reported | [(0.05)](/filings/0001493152-26-038477.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [55.3](/filings/0001493152-23-040989.md) | [80.1](/filings/0001493152-24-005908.md) | [87.4](/filings/0001493152-25-006783.md) | [12.4](/filings/0001493152-24-032139.md) | [126](/filings/0001493152-24-045778.md) | [28.9](/filings/0001493152-25-006783.md) | [228](/filings/0001493152-26-031136.md) | [3,304](/filings/0001493152-25-011967.md) | [768](/filings/0001493152-25-023398.md) | [18.2](/filings/0001493152-26-007150.md) | [201](/filings/0001493152-26-038477.md) | [123](/filings/0001493152-26-038477.md) |
| Current assets | $k | [2,016](/filings/0001493152-23-040989.md) | [1,493](/filings/0001493152-24-005908.md) | [1,042](/filings/0001641172-25-018617.md) | [880](/filings/0001493152-24-032139.md) | [1,246](/filings/0001493152-24-045778.md) | [1,227](/filings/0001493152-25-006783.md) | [5,610](/filings/0001493152-26-031136.md) | [4,401](/filings/0001493152-25-011967.md) | [2,110](/filings/0001493152-25-023398.md) | [1,383](/filings/0001493152-26-007150.md) | [1,710](/filings/0001493152-26-038477.md) | [941](/filings/0001493152-26-038477.md) |
| Total assets | $k | [4,062](/filings/0001493152-23-040989.md) | [3,630](/filings/0001493152-24-005908.md) | [3,115](/filings/0001641172-25-018617.md) | [2,889](/filings/0001493152-24-032139.md) | [3,187](/filings/0001493152-24-045778.md) | [3,112](/filings/0001493152-25-006783.md) | [9,339](/filings/0001493152-26-031136.md) | [6,890](/filings/0001493152-25-011967.md) | [5,258](/filings/0001493152-25-023398.md) | [4,376](/filings/0001493152-26-007150.md) | [3,577](/filings/0001493152-26-038477.md) | [2,669](/filings/0001493152-26-038477.md) |
| Current liabilities | $k | [1,915](/filings/0001493152-23-040989.md) | [1,662](/filings/0001493152-24-005908.md) | [1,412](/filings/0001641172-25-018617.md) | [1,091](/filings/0001493152-24-032139.md) | [1,858](/filings/0001493152-24-045778.md) | [2,936](/filings/0001493152-25-006783.md) | [4,317](/filings/0001493152-26-031136.md) | [3,117](/filings/0001493152-25-011967.md) | [1,053](/filings/0001493152-25-023398.md) | [988](/filings/0001493152-26-007150.md) | [1,377](/filings/0001493152-26-038477.md) | [1,313](/filings/0001493152-26-038477.md) |
| Total liabilities | $k | [3,073](/filings/0001493152-23-040989.md) | [2,735](/filings/0001493152-24-005908.md) | [2,429](/filings/0001641172-25-018617.md) | [2,059](/filings/0001493152-24-032139.md) | [2,778](/filings/0001493152-24-045778.md) | [3,807](/filings/0001493152-25-006783.md) | [5,120](/filings/0001493152-26-031136.md) | [3,160](/filings/0001493152-25-011967.md) | [1,075](/filings/0001493152-25-023398.md) | [997](/filings/0001493152-26-007150.md) | [1,377](/filings/0001493152-26-038477.md) | [1,313](/filings/0001493152-26-038477.md) |
| Long-term debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [989](/filings/0001493152-25-006783.md) | [895](/filings/0001493152-25-006783.md) | [686](/filings/0001493152-26-031136.md) | [830](/filings/0001493152-26-007150.md) | [409](/filings/0001493152-26-007150.md) | [(695)](/filings/0001493152-26-007150.md) | [4,219](/filings/0001493152-26-038477.md) | [2,968](/filings/0001493152-26-038477.md) | [4,183](/filings/0001493152-26-007150.md) | [3,379](/filings/0001493152-26-007150.md) | [2,199](/filings/0001493152-26-038477.md) | [1,356](/filings/0001493152-26-038477.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,442) d](/filings/0001493152-24-045778.md) | [(1,291) d](/filings/0001493152-25-006783.md) | [(1,524) d](/filings/0001641172-25-018617.md) | [(1,530)](/filings/0001493152-25-011967.md) | [(1,600) d](/filings/0001493152-25-023398.md) | [(961) d](/filings/0001493152-26-007150.md) | [(1,230) d](/filings/0001493152-26-031136.md) | [(1,634)](/filings/0001493152-26-038477.md) | [(2,194) d](/filings/0001493152-25-023398.md) | [(1,467) d](/filings/0001493152-26-007150.md) | [(812) d](/filings/0001493152-26-031136.md) | [(966)](/filings/0001493152-26-038477.md) |
| Capital expenditure | $k | [46.2 d](/filings/0001493152-24-045778.md) | [186 d](/filings/0001493152-25-006783.md) | [29.3 d](/filings/0001641172-25-018617.md) | [15.2](/filings/0001493152-25-011967.md) | [3.4 d](/filings/0001493152-25-023398.md) | [23.6 d](/filings/0001493152-26-007150.md) | [21.2 d](/filings/0001493152-26-031136.md) | not reported | not reported | [(5.2) d](/filings/0001493152-26-007150.md) | [0.0 d](/filings/0001493152-26-031136.md) | [12.4](/filings/0001493152-26-038477.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.1](/filings/0001493152-23-040989.md) | [10.1](/filings/0001493152-24-005908.md) | [11.7](/filings/0001493152-24-032139.md) | [13.0](/filings/0001493152-24-045778.md) | [14.3](/filings/0001493152-25-006783.md) | [18.7](/filings/0001493152-25-011967.md) | [20.1](/filings/0001493152-25-023398.md) | [20.6](/filings/0001493152-26-007150.md) | [24.3](/filings/0001493152-26-038477.md) | [27.6](/filings/0001493152-25-023398.md) | [33.7](/filings/0001493152-26-007150.md) | [37.1](/filings/0001493152-26-038477.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 37,950,495 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038477.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.